TPTE

Across TCGA pan-cancer cohorts, TPTE Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TPTE data layer compared with 14 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TPTE Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TPTE expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and COAD are the cancer types where TPTE Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	All	0.511	0.842	<.001	30	view →
UCEC	DFS	Median	All	1.000	0.633	.013	24	view →
COAD	DFS	Median	II,III,IV	0.243	0.665	.006	18	view →
LUSC	DFS	Median	III,IV	0.045	0.790	<.001	14	view →
SKCM	DFS	Median	II,III,IV	0.509	0.722	.010	6	view →
LGG	OS	Median	All	0.332	0.830	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TPTE–OV (OS)

Open the OV breakdown →